Literature DB >> 15475754

Pneumocystis jiroveci (carinii) pneumonia following initiation of infliximab and azathioprine therapy in a patient with Crohn's disease.

Mimouna Seddik1, Hugues Meliez, David Seguy, Nathalie Viget, Antoine Cortot, Jean Frederic Colombel.   

Abstract

Anti-TNFalpha therapy is an effective treatment of Crohn's disease. There is an increased risk of infection, including atypical infection associated in infliximab treated patients. We report a case of a young man who developed Pneumocystisjiroveci pneumonia shortly after starting therapy with infliximab. Thus, although rare, prophylaxis against Pneumocystis jiroveci pneumonia might be considered when starting a treatment with infliximab, especially in patients receiving concomitant immunosuppressive agents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15475754     DOI: 10.1097/00054725-200407000-00017

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  11 in total

1.  Cost-effectiveness of Prophylaxis Against Pneumocystis jiroveci Pneumonia in Patients with Crohn's Disease.

Authors:  Philip N Okafor; Francis A Farraye; Adetoro T Okafor; Daniel O Erim
Journal:  Dig Dis Sci       Date:  2015-07-16       Impact factor: 3.199

2.  Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression.

Authors:  Thomas G Cotter; Nicola Gathaiya; Jelena Catania; Edward V Loftus; William J Tremaine; Larry M Baddour; W Scott Harmsen; Alan R Zinsmeister; William J Sandborn; Andrew H Limper; Darrell S Pardi
Journal:  Clin Gastroenterol Hepatol       Date:  2016-12-21       Impact factor: 11.382

3.  Anti-TNFα antibody infliximab treatment for an infant with fistulising Crohn's disease.

Authors:  Omar I Saadah
Journal:  BMJ Case Rep       Date:  2010-01-13

4.  Pneumocystis pneumonia complicating immunosuppressive therapy in Crohns disease: A preventable problem?

Authors:  Omer Omer; Patrizia Cohen; Shuet Fong Neong; Geoffrey V Smith
Journal:  Frontline Gastroenterol       Date:  2014-09-22

5.  B cell production of tumor necrosis factor in response to Pneumocystis murina infection in mice.

Authors:  Michael M Opata; Zhan Ye; Melissa Hollifield; Beth A Garvy
Journal:  Infect Immun       Date:  2013-09-03       Impact factor: 3.441

Review 6.  COVID-19-associated opportunistic infections: a snapshot on the current reports.

Authors:  Amir Abdoli; Shahab Falahi; Azra Kenarkoohi
Journal:  Clin Exp Med       Date:  2021-08-23       Impact factor: 5.057

7.  Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximab.

Authors:  Alan C Moss; Kyung Jo Kim; Nielsen Fernandez-Becker; Didia Cury; Adam S Cheifetz
Journal:  Dig Dis Sci       Date:  2009-06-18       Impact factor: 3.199

8.  Risk Factors for Mortality in Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease.

Authors:  Atsushi Yoshida; Noriko Kamata; Akihiro Yamada; Yoko Yokoyama; Teppei Omori; Toshimitsu Fujii; Ryohei Hayashi; Tetsu Kinjo; Akira Matsui; Norimasa Fukata; Sakuma Takahashi; Ryosuke Sakemi; Noriyuki Ogata; Shinya Ashizuka; Shigeki Bamba; Makoto Ooi; Shuji Kanmura; Katsuya Endo; Takuya Yoshino; Hiroki Tanaka; Toshio Morizane; Shinichiro Shinzaki; Taku Kobayashi
Journal:  Inflamm Intest Dis       Date:  2019-02-06

9.  Pneumocystis pneumonia during combined therapy of infliximab, corticosteroid, and azathioprine in a patient with Crohn's disease.

Authors:  Soichi Itaba; Tsutomu Iwasa; Yojiro Sadamoto; Toshifumi Nasu; Tadashi Misawa; Koji Inoue; Hidehiko Shimokawa; Kazuhiko Nakamura; Ryoichi Takayanagi
Journal:  Dig Dis Sci       Date:  2007-04-03       Impact factor: 3.487

10.  Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study.

Authors:  Takayuki Katsuyama; Kazuyoshi Saito; Satoshi Kubo; Masao Nawata; Yoshiya Tanaka
Journal:  Arthritis Res Ther       Date:  2014-02-05       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.